ISLAMABAD ( Web News ) Prime Minister Imran Khan’s Telephone Call with Bill Gates to Discuss Polio Eradication and other Public Health Related Matters Prime Minister Imran Khan spoke with Mr. Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation (BMGF). Views were exchanged on the ongoing polio eradicationRead More →
ISLAMABAD ( Web News ) Uber, the global ride-hailing platform that seamlessly connects riders with drivers, in an attempt to extend its commitment towards education development, has collaborated with the United Nations Educational, Scientific, and Cultural Organization (UNESCO) to provide free rides to teachers to and from their respective vaccinationRead More →
Supply to be provided over the course of 2021 Agreement is part of Pfizer’s and BioNTech’s global commitment to help address the COVID-19 pandemic ISLAMABAD ( Web News ) Pfizer Pakistan and BioNTech SE today announced an agreement with the National Disaster Management Authority, Government of Pakistan to supply 13 million doses of their COVID-19 Vaccine (BNT162b2). Deliveries are planned during course of 2021. “We are deeply honored to work with the Pakistan government and to marshal our scientific and manufacturing resources toward our shared goal of bringing a COVID-19 vaccine to the people of Pakistan as quickly as possible,” said Syed Muhammad Wajeehuddin, Country Manager Pfizer Pakistan. “In the face of this global health crisis, Pfizer’s purpose – breakthroughs that change patients’ lives – has taken on an even greater urgency. Our hope is that our vaccine will help make this happen.” “I would like to thank the Pakistan government for its support and putting trust in our ability to develop a vaccine that, we believe, has the potential to help address this global pandemic threat. Our goal remains to deliver a global supply of a well-tolerated and effective COVID-19 vaccine for many people around the world, as quickly as we can,” said Sean Marett, Chief Business and Chief Commercial Officer at BioNTech. Pfizer and BioNTech aim to manufacture more than 3 billion doses of their COVID-19 vaccine globally in total by the end of 2021, assuming updated six-dose labeling, continuous process improvements, expansion at current facilities and contingent upon adding new suppliers and contract manufacturers. The vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer, and the marketing authorization holder is BioNTech in the United States, Europe, U.K., Canada, and other countries.Read More →